necess
cultur
microbiolog
line
avail
start
autom
plate
streaker
end
molecular
identif
organ
grown
solid
media
despit
molecular
technolog
advanc
human
must
still
view
cultur
plate
perhap
televis
screen
select
coloni
analyz
furthermor
although
cost
contain
paramount
import
today
medic
marketplac
cheaper
ambigu
target
microbiolog
laboratori
diagnost
facil
drive
subsequ
therapi
increas
laboratori
cost
rapid
microbi
identif
shown
result
earlier
use
appropri
antibiot
shorter
durat
hospit
stay
better
outcom
decreas
overal
health
care
cost
diagnosi
persist
human
papilloma
viru
hpv
infect
follow
appropri
therapeut
intervent
decreas
incid
cervic
carcinoma
cost
treatment
attribut
morbid
mortal
new
technolog
enabl
microbiolog
investig
includ
origin
diagnost
approach
nextgener
sequenc
ng
detect
quantifi
popul
organ
patient
specimen
rais
possibl
distinguish
pathogen
organ
present
high
number
colon
gener
presum
present
lower
number
certain
colon
organ
profil
seem
correl
develop
cardiovascular
diseas
patient
colon
flora
could
analyz
profil
unfavor
bacteria
could
erad
replac
test
use
evolv
significantli
cite
review
continu
thu
articl
snapshot
rapidli
chang
diagnost
microbiolog
laboratori
techniqu
clinic
applic
emphasi
place
test
high
market
share
diagnost
microbiolog
technolog
person
regard
author
particularli
interest
role
specimen
process
concentr
nucleic
acid
target
remov
inhibitor
amplif
larg
neglect
despit
import
role
sensit
assay
howev
mani
new
procedur
autom
includ
specimen
process
part
handsoff
procedur
techniqu
mention
involv
realtim
pcr
rtpcr
unless
otherwis
specifi
rtpcr
platform
close
system
decreas
incid
amplicon
contamin
laboratori
allow
mani
nucleic
acid
amplif
techniqu
becom
commerci
avail
author
also
attempt
select
current
citat
support
salient
point
select
arbitrari
failur
mention
public
techniqu
trade
name
constru
denigr
articl
techniqu
manufactur
first
molecular
diagnost
test
approv
fda
probe
techniqu
mani
probe
test
still
wide
use
today
fill
import
nich
involv
novel
detect
methodolog
among
first
fdaapprov
molecular
test
genprob
san
diego
ca
becam
wholli
own
subsidiari
holog
bedford
pace
probe
hybrid
protect
techniqu
use
diagnosi
chlamydia
trachomati
neisseria
gonorrhoea
patient
specimen
larg
replac
sensit
amplif
test
number
accuprob
cultur
confirm
test
remain
avail
among
use
mycobacterium
tuberculosi
complex
mycobacterium
avium
mycobacterium
intracellular
separ
togeth
mycobacterium
kansasii
mycobacterium
gordoni
test
avail
manufactur
use
reagent
instrument
facilit
use
multipl
assay
laboratori
test
succeed
target
ribosom
rna
rrna
present
copi
per
organ
bacteri
ribosom
common
sequenc
well
genusspecif
speciesspecif
sequenc
cultur
confirm
test
remain
viabl
intend
detect
organ
visibl
coloni
liquid
medium
detect
growth
thu
amplif
step
alreadi
perform
natur
sensit
report
hologicgenprob
packag
insert
rang
develop
assay
novel
nonradioact
perform
total
solut
sampl
transfer
step
nucleic
acid
extract
hybrid
protect
assay
base
differenti
sensit
acridinium
ester
use
distinguish
rel
labil
ester
nonhybrid
probe
stabl
form
dnarna
hybrid
detect
system
also
use
manufactur
nucleic
acid
amplif
test
naat
accuprob
assay
similar
nucleic
acid
releas
step
variabl
depend
eas
disrupt
organ
mycobacteri
probe
test
particularli
valuabl
use
conjunct
liquid
medium
thinplat
techniqu
use
rapid
detect
identif
mycobacteria
requir
colleg
american
pathologist
northfield
il
thinplat
coloni
probe
day
detect
morpholog
use
guid
select
appropri
probe
repres
signific
time
money
save
although
elimin
need
grow
tuberculosi
suscept
test
cultur
middlebrook
broth
must
afb
stain
confirm
presenc
mycobacteria
probe
probe
probe
techniqu
describ
also
use
detect
amplif
product
amplif
assay
develop
genprobeholog
sexual
transmit
diseas
blood
bank
test
discuss
elsewher
articl
sinc
pap
smear
contribut
great
advanc
prevent
diagnosi
cervic
carcinoma
recogn
infect
hpv
necessari
suffici
develop
cervic
carcinoma
hpv
genotyp
exist
associ
high
risk
cervic
carcinoma
sexual
activ
women
becom
infect
hpv
infect
even
highrisk
organ
resolv
without
appar
sequala
other
progress
still
unknown
digen
hybrid
captur
qiagen
gaithersburg
md
fda
approv
primari
screen
determin
whether
women
atyp
squamou
cell
undetermin
signific
subject
culposcopi
may
use
cytyc
preservcyt
solut
cytyc
thinprep
pap
test
holog
first
step
patient
specimen
allow
react
pool
rna
probe
design
hybrid
specif
dna
highrisk
hpv
strain
antibodi
rnadna
hybrid
coat
well
microtit
plate
captur
hybrid
wash
away
unbound
specimen
reagent
detector
antihybrid
antibodi
conjug
multipl
molecul
alkalin
phosphatas
bind
captur
target
therebi
amplifi
signal
colorless
substrat
alkalin
phosphatas
ad
chemiluminesc
develop
proport
amount
second
antibodi
bound
sensit
test
typic
involv
target
amplif
devis
clinic
outcom
data
avail
need
sensit
question
alreadi
shown
sensit
highli
specif
develop
cervic
intraepitheli
neoplasia
overt
malign
presenc
highrisk
dna
detect
limit
seem
associ
low
risk
malign
howev
new
inform
suggest
infect
acquir
earli
year
sexual
activ
may
reactiv
age
support
studi
sensit
assay
might
indic
also
suggest
unusu
hpv
strain
may
caus
cervic
carcinoma
precursor
lesion
restrict
popul
thu
strain
includ
assay
may
need
period
review
amplif
techniqu
avail
distinguish
highrisk
organ
facilit
target
followup
algorithm
outcom
data
increas
uniqu
probe
techniqu
becom
less
common
use
hybrid
captur
basi
detect
system
amplif
assay
still
possibl
use
assay
howev
consid
method
high
sensit
peptid
nucleic
acid
fluoresc
situ
hybrid
pnafish
advandx
inc
woburn
own
opgen
acceler
diagnosi
sepsi
common
agent
sepsi
identifi
hour
blood
cultur
bottl
gram
stain
although
behav
like
standard
fish
assay
pnafish
probe
consist
uncharg
peptid
backbon
base
attach
thought
allow
probe
enter
permeabil
bacteri
cell
easili
bind
tightli
neg
charg
rrna
target
numer
public
confirm
use
techniqu
rapid
identif
common
organ
grow
blood
cultur
bottl
improv
antibiot
stewardship
shorten
length
stay
depend
patient
identif
coagulaseneg
staphylococcu
may
facilit
discontinu
antibiot
earli
discharg
highthroughput
laboratori
blood
cultur
per
day
earli
adapt
staphylococc
enterococc
candida
probe
although
current
use
bacteria
owe
avail
sensit
platform
abil
detect
great
number
pathogen
involv
bacteremia
sepsi
multipl
pnafish
assay
receiv
fda
clearanc
includ
assay
detect
staphylococcu
aureuscoagulaseneg
staphylococcu
enterococuu
fecalis
faceium
gramneg
traffic
light
identif
e
coli
klebsiella
penumonia
pseudomona
aeruginosa
yeast
traffic
light
identif
candida
albican
c
krusei
c
tropicali
c
glabrata
c
parapsilosi
laboratori
involv
clinic
trial
advandx
pnafish
product
data
show
high
sensit
specif
product
well
eas
use
although
popular
pnafish
diagnost
test
larg
laboratori
declin
fish
techniqu
use
acceler
diagnost
tucson
az
facilit
organ
identif
posit
blood
cultur
bottl
affirm
vpiii
microbi
identif
test
vpiii
probe
test
becton
dickinson
franklin
lake
nj
intend
diagnosi
vaginitisvaginosi
condit
caus
million
physician
visit
annual
affirm
detect
rrna
gardnerella
vaginali
use
indic
bacteri
vaginosi
bv
c
albican
trichomona
vaginali
sensit
adjust
avoid
give
posit
result
low
concentr
g
vaginali
c
albican
often
colon
normal
vagina
use
later
flow
immunochromatograph
enzym
assay
assay
maintain
low
sensit
requir
copi
trichomona
nucleic
acid
give
posit
result
may
ideal
gardnerella
bad
trichomona
speci
format
perform
cassett
superfici
resembl
later
flow
test
use
serolog
detect
influenza
rotaviru
antigen
first
fdaapprov
molecular
test
base
later
flow
methodolog
later
flow
follow
collect
proprietari
swab
specimen
lyse
releas
nucleic
acid
buffer
stabil
nucleic
acid
establish
stringenc
ad
cassett
incub
proper
temperatur
nucleic
acid
hybrid
cassett
contain
bead
coupl
captur
probe
analyt
plu
posit
neg
control
next
enzymelink
detector
probe
bind
specif
sequenc
target
organ
rrna
unbound
sampl
compon
probe
wash
away
colorless
substrat
convert
blue
product
suffici
target
detector
probe
bound
blue
bead
indic
posit
result
numer
public
reveal
health
care
provid
significantli
less
accur
vpiii
diagnosi
signific
candidiasi
vaginali
affirm
test
highlight
fact
multipl
infect
common
role
vpiii
diagnosi
bv
subject
debat
howev
use
g
vaginali
alon
indic
bv
optim
addit
critic
limit
detect
lod
assay
particularli
vaginali
inabl
assay
highlight
presenc
drugresist
candida
spp
autom
naat
assay
includ
max
vagin
panel
assay
becton
dickinson
resolv
mani
problem
becton
dickinson
suggest
affirm
assay
may
appropri
smaller
laboratori
wherea
larger
laboratori
may
wish
transit
naat
assay
becton
dickinson
max
vagin
panel
first
fda
clear
microbiomebas
pcr
assay
directli
detect
common
infecti
caus
vagin
bv
vulvovagin
candidiasi
trichomoniasi
max
vagin
panel
perform
becton
dickinson
max
instrument
fulli
autom
diagnos
bv
use
uniqu
algorithm
quantit
presenc
lactobacillu
spp
good
bacteria
compar
g
vaginali
atopobium
vagina
bvassoci
bacteria
megasphera
bvassoci
bacteria
separ
determin
presenc
vaginali
well
presenc
candida
group
albican
tropicali
parapsilosi
dublinensi
c
glabrata
c
krusei
antibiot
resist
cultur
immunoassay
probe
test
n
gonorrhoea
also
known
gonococci
c
trachomati
less
sensit
naat
naat
standard
care
sinc
late
although
certain
jurisdict
still
requir
cultur
legal
case
text
n
gonorrhoea
gonococci
use
interchang
c
trachomati
gonococc
infect
femal
genit
tract
present
diagnost
challeng
mani
patient
c
trachomati
gonococci
asymptomat
sexual
transmit
diseas
becom
preval
even
unit
state
europ
led
implement
widespread
screen
use
urin
selfcollect
swab
collect
procedur
increas
patient
accept
test
also
avail
physiciancollect
vagin
swab
male
urethr
swab
urin
commerci
qualit
naat
diagnosi
c
trachomati
gonococci
avail
year
first
pcr
assay
semiautom
amplicor
c
trachomatisn
gonorrhoea
test
develop
roch
basel
switzerland
close
follow
abbott
lcx
assay
abbott
laboratori
chicago
il
diagnost
molecular
microbiolog
simultan
detect
c
trachomati
n
gonorrhoea
use
ligas
chain
reaction
technolog
amplifi
target
abbott
lcx
assay
c
trachomati
gonococci
withdrawn
abruptli
market
late
amplif
assay
becam
avail
stranddisplac
amplif
assay
becton
dickinson
probetec
et
transcriptionmedi
amplif
test
genprob
introduc
evolv
year
addit
test
also
fda
approv
test
approach
includ
becton
dickinson
probetec
c
trachomatisgonococci
qx
assay
perform
viper
xtr
hologicgenprob
aptima
combo
assay
perform
panther
tigri
instrument
abbott
realtim
c
trachomatisn
gonorrhoea
assay
roch
diagnost
coba
c
trachomatisn
gonorrhoea
assay
run
coba
instrument
current
problem
molecular
diagnost
test
c
trachomatisgonococci
inabl
test
antibiot
resist
n
gonorrhoea
inexor
develop
resist
antibiot
regimen
becam
wide
use
question
antimicrobi
resist
c
trachomati
hardli
consid
although
treatment
failur
wellknown
transport
system
c
trachomati
gonococci
compat
cultur
suscept
test
seem
inevit
molecular
suscept
test
must
develop
unawar
develop
assay
perform
either
tigri
panther
instrument
target
region
rrna
c
trachomati
one
rrna
gonococci
amplifi
via
dna
intermedi
use
transcriptionmedi
amplif
techniqu
use
revers
transcriptas
enzym
phagederiv
rnadepend
rna
polymeras
detect
amplicon
achiev
use
hybrid
protect
assay
describ
herein
section
probe
test
briefli
singlestrand
chemiluminesc
dna
probe
bind
complementari
target
protect
labil
acridinium
ester
hydrolysi
ester
unbound
probe
light
emit
ester
protect
within
targetprob
hybrid
measur
report
rel
light
unit
assay
result
determin
cutoff
base
total
rel
light
unit
curv
type
becton
dickinson
probetec
c
trachomatisgonococci
qx
assay
viper
xtr
assay
use
isotherm
dna
nick
translat
techniqu
call
stranddisplac
amplif
detect
target
sequenc
patient
sampl
target
sequenc
cryptic
c
trachomati
plasmid
sequenc
gonococci
genom
dna
respect
extract
dna
clinic
sampl
base
phdepend
bind
dna
ferric
oxid
particl
follow
bind
combin
paramagnet
bead
remov
contamin
purifi
dna
releas
amplifi
realtim
stranddisplac
amplif
presenc
fluoresc
label
detector
probe
presenc
target
dna
determin
compar
peak
fluoresc
cutoff
valu
mani
articl
discuss
perform
assay
detect
target
clinic
specimen
urin
vaginalcerv
sampl
assay
evalu
pregnant
women
well
patient
younger
year
age
abbott
realtim
c
trachomatisn
gonorrhoea
assay
rtpcr
assay
target
sequenc
within
cryptic
plasmid
c
trachomati
plasmid
found
serovar
chlamydia
date
dual
target
allow
detect
wildtyp
c
trachomati
variant
delet
one
target
sequenc
gonococci
target
found
within
organ
opa
gene
cheng
colleagu
evalu
abbott
realtim
c
trachomatisgonococci
assay
comparison
roch
coba
amplicor
c
trachomatisn
gonorrhoea
assay
show
high
agreement
assay
howev
data
demonstr
abbott
assay
sensit
roch
assay
c
trachomati
n
gonorrhoea
enhanc
abil
detect
dual
infect
multiplex
pcr
assay
simultan
detect
independ
dna
target
c
trachomati
one
cryptic
plasmid
c
trachomati
genom
assay
detect
infect
caus
wildtyp
c
trachomati
addit
chlamydia
strain
may
delet
cryptic
plasmid
might
carri
cryptic
plasmid
direct
repeat
region
target
n
gonorrhoea
assay
use
target
make
assay
highli
specif
n
gonorrhoea
target
crossreact
sequenc
found
commens
neisseria
featur
hamper
use
gonococci
assay
oropharyng
rectal
sampl
cherneski
colleagu
perform
direct
comparison
secondgener
c
trachomatisgonococci
assay
obtain
inform
rel
sensit
specif
use
first
void
urin
selfcollect
vagin
swab
sensit
c
trachomati
use
selfcollect
swab
aptima
combo
run
tigri
panther
hologicgenprob
realtim
assay
abbott
probetec
q
x
assay
viper
becton
dickinson
coba
assay
test
coba
roch
hologicgenprob
manufactur
sever
wide
use
qualit
transcriptionmedi
amplificationbas
microbiolog
test
includ
among
direct
test
tuberculosi
procleix
ultrio
plu
assay
ultrio
also
licens
novarti
emoryvil
ca
first
assay
without
plu
long
approv
detect
human
immunodefici
viru
hiv
hepat
c
viru
hcv
specimen
blood
donor
organ
donor
live
deceas
intend
diagnost
workup
diseas
gener
popul
test
pool
sampl
blood
donor
unit
approv
blood
bank
test
recent
fda
approv
inclus
hepat
b
viru
assay
renam
ultrio
plu
contain
sever
hiv
target
allow
detect
sever
strain
test
result
gener
neg
high
sensit
necessari
inclus
intern
control
essenti
compon
posit
pool
retest
individu
assay
individu
analyt
publish
data
contain
list
publish
rtpcr
assay
develop
detect
speci
bacteria
list
includ
multiplex
test
assay
virus
public
acknowledg
list
incomplet
comment
laboratorydevelop
test
count
list
commerci
avail
whether
fda
approv
find
emphas
need
rapid
commerci
develop
fda
approv
method
although
cyber
green
nonspecif
detector
still
use
occasion
main
molecular
detect
system
use
dual
hybrid
fluoresc
reson
energi
transfer
taqman
molecular
beacon
fluoresc
reson
energi
transfer
detector
consist
differ
probe
complementari
adjac
sequenc
target
amplicon
attach
differ
fluorophor
activ
incid
ultraviolet
light
first
fluorophor
emit
energi
unmonitor
wavelength
second
probe
bound
adjac
energi
transfer
second
fluorophor
emit
light
wavelength
monitor
sensor
end
pcr
assay
melt
curv
ampliconprob
complex
gener
melt
temperatur
characterist
ampliconprob
combin
mismatch
probe
amplicon
melt
temperatur
decreas
melt
temperatur
differ
exploit
test
distinguish
herp
simplex
roch
pcr
primer
bind
sequenc
common
virus
within
hsv
dna
polymeras
gene
amplicon
detector
probe
match
sequenc
differ
bp
melt
curv
analysi
reveal
reproduc
melt
temperatur
c
higher
exhibit
occasion
mutant
hsv
strain
detect
intermedi
melt
temperatur
test
report
posit
hsv
type
clear
type
could
distinguish
sequenc
amplicon
use
assay
use
differ
target
sequenc
melt
temperatur
amplicon
said
c
higher
variant
type
variant
multicod
rtx
system
use
unusu
pcr
amplif
techniqu
detector
probe
use
fluoresc
actual
decreas
amplif
progress
develop
eragen
bioscienc
inc
madison
wi
acquir
luminex
corpor
austin
tx
multicodertx
herp
simplex
viru
kit
fda
approv
multicod
rtx
assay
use
unusu
nucleotid
base
ic
ig
base
pair
one
anoth
effici
incorpor
pcr
product
ig
put
end
rtx
primer
along
link
fluorophor
reaction
mix
contain
ic
coval
link
quencher
initi
cycl
amplif
ig
attach
fluorophor
appear
end
primer
henc
end
nascent
amplicon
strand
serv
templat
copi
direct
ic
attach
quencher
ad
end
new
strand
opposit
ig
fluorophor
approxim
fluorophor
quencher
decreas
fluoresc
melt
curv
analysi
fluoresc
increas
amplicon
melt
melt
temperatur
allow
determin
natur
analyt
quantit
pcr
clinic
microbiolog
confin
mainli
naat
use
hiv
viral
load
test
although
also
fdaapprov
quantit
rtpcr
assay
hcv
hepat
b
viru
recent
cytomegaloviru
trend
make
assay
refer
world
health
organ
intern
standard
quantit
techniqu
advanc
significantli
sinc
earli
day
alic
huang
first
demonstr
quantit
pcr
possibl
detail
discuss
review
literatur
see
fairfax
salimnia
rtpcr
inher
semiquantit
theoret
one
construct
standard
curv
copi
number
versu
cycl
thresholdand
determin
quantiti
analyt
patient
specimen
refer
curv
howev
variat
extract
effici
presenc
inhibitor
introduc
signific
error
particularli
low
level
analyt
one
attempt
distinguish
none
one
rel
straightforward
method
overcom
problem
includ
addit
control
target
quantit
standard
patient
sampl
extract
target
quantit
standard
extract
amplifi
detect
togeth
control
extract
inhibitor
present
ideal
quantit
standard
size
base
composit
target
quantifi
primer
bind
site
differ
enough
sequenc
detector
probe
probe
target
bind
detector
probe
fluoresc
differ
wavelength
target
quantit
simpl
mathemat
calcul
howev
low
target
concentr
standard
curv
longer
straight
roch
incorpor
complex
mathemat
calcul
recent
viral
load
assay
account
diverg
convers
recent
begun
possibl
cure
hiv
infect
highli
activ
antiretrovir
therapi
improv
plasma
hiv
viral
load
techniqu
converg
discuss
ensu
evalu
residu
viru
wellcontrol
possibl
cure
individu
sensit
assay
determin
lowlevel
infect
like
assay
hiv
dna
copi
singl
cell
determin
one
replic
compet
crucial
discuss
asid
circul
cell
cell
investig
unclear
time
activ
area
investig
recent
review
strain
richman
discuss
lowlevel
contamin
signaltonois
ratio
pcr
test
singlecel
pcr
techniqu
beyond
scope
articl
respect
hiv
quantif
plasma
consider
affect
test
result
interpret
obviou
problem
result
increas
sensit
assay
improv
patient
told
viru
level
undetect
suddenli
quantifi
viru
timeconsum
correl
viral
load
prognosi
redon
new
sensit
assay
sequenc
differ
numer
organ
strain
inher
mutabl
organ
also
make
accur
quantif
difficult
especi
rna
virus
hiv
hcv
one
must
target
stabl
sequenc
howev
viral
rna
polymeras
enzym
error
prone
lack
proofread
activ
chang
genet
sequenc
particularli
primer
probebind
site
may
reduc
detect
viral
load
minor
quasispeci
also
caus
problem
discuss
elsewher
articl
seem
target
necessari
futur
assay
approv
releas
diagnost
test
differ
manufactur
coordin
difficult
find
articl
compar
perform
latest
offer
differ
compani
two
current
assay
hiv
quantif
unit
state
roch
coba
ampliprep
coba
taqman
hiv
viral
load
version
abbott
realtim
assay
art
hiv
assay
differ
lower
limit
quantit
copiesml
copiesml
art
hiv
introduc
difficulti
comparison
howev
compar
recent
articl
sire
colleagu
extrapol
art
hiv
curv
found
specimen
quantifi
art
hiv
could
actual
quantifi
assay
correl
well
r
although
log
higher
art
hiv
sampl
wherea
art
hiv
log
higher
whose
result
accur
remain
determin
section
focus
highli
multiplex
assay
roughli
defin
detect
target
although
mani
assay
individu
etiolog
diagnost
molecular
microbiolog
agent
diseas
avail
test
individu
organ
often
uninform
numer
viral
bacteri
agent
respiratori
diseas
caus
similar
symptom
usual
obviou
agent
agent
infect
given
patient
even
peak
influenza
epidem
individu
may
infect
respiratori
syncyti
viru
instead
concurr
furthermor
mix
infect
common
mani
imagin
viru
infect
treatabl
other
differ
isol
requir
patient
hospit
thu
molecular
panel
could
detect
multipl
etiolog
agent
diseas
clearli
desir
decemb
multiplex
respiratori
panel
fda
approv
luminex
xtag
rvp
xrvp
rvp
fast
xrvpf
verigen
respiratori
pathogen
flex
luminex
corpor
film
array
respiratori
panel
farp
biofir
diagnost
biomerieux
salt
lake
citi
ut
esensor
respiratori
viral
panel
eplex
respiratori
pathogen
panel
genmark
diagnost
carlsbad
ca
comparison
system
farp
detect
greatest
number
pathogen
includ
bacteria
viral
pathogen
one
headtohead
comparison
test
modal
recent
publish
variou
analyt
differ
sensit
specif
studi
found
esrp
sensit
analyt
compar
xrvp
second
sensit
xrvpf
similar
farp
result
requir
confirm
research
babadi
colleagu
found
farp
sensit
xrvpf
mani
analyt
test
capabl
detect
mix
infect
ultim
final
decis
test
implement
one
laboratori
may
come
question
cost
handson
time
complex
time
result
conveni
farp
provid
result
within
hour
requir
minut
handson
time
handl
sampl
time
seem
ideal
suit
mediums
laboratori
technologist
without
special
molecular
expertis
perform
test
larger
laboratori
bought
multipl
instrument
instrument
higher
throughput
eg
torch
biofir
facilit
throughput
surg
capac
may
lack
system
test
sampl
batch
mode
high
throughput
requir
sampl
extract
test
amplicon
manipul
afterward
may
confin
pcr
laboratori
handl
sampl
per
run
none
suitabl
run
per
shift
although
stagger
technologist
start
time
could
allow
xrvpf
xrvp
esrp
requir
hour
result
problem
panel
tend
maxim
number
analyt
detect
initi
offer
base
instrument
constraint
therefor
ad
someth
new
seem
requir
someth
old
remov
html
appar
high
mortal
rate
human
metapneumovirus
human
bocaviru
includ
previous
mention
assay
clear
whether
mer
corona
viru
detect
coronaviru
detector
system
assay
could
distinguish
caus
common
respiratori
infect
thu
keep
panel
updat
may
prove
difficult
new
multiplex
panel
develop
receiv
fda
clearanc
viral
parasit
bacteri
agent
gastrointestin
diseas
central
nervou
system
infect
biofir
assay
usual
agent
bloodstream
infect
fda
approv
august
biofir
gastrointestin
panel
mening
panel
also
receiv
fda
clearanc
may
novemb
respect
addit
detect
bacteri
pathogen
detect
sever
antibiot
resist
gene
anoth
system
known
verigen
bloodstream
test
made
nanosher
luminex
corpor
provid
bacteri
identif
antibiot
resist
determin
directli
posit
blood
cultur
bottl
assay
includ
cartridg
gram
posit
gram
neg
gram
stain
posit
blood
cultur
bottl
need
decid
gramposit
gramneg
cartridg
use
luminex
biofir
also
offer
fdaclear
gastrointestin
panel
detect
identifi
viral
bacteri
toxin
directli
stool
sampl
wherea
blood
cultur
panel
run
posit
cultur
bottl
may
take
day
becom
posit
detect
sever
antibiot
resist
gene
well
infect
bacteria
proveit
sepsi
assay
identifi
bacteria
fungi
posit
blood
cultur
hour
assay
approv
europ
fda
clear
unit
state
proveit
sepsi
run
strip
well
identifi
sampl
microarray
identifi
bacteria
meca
vana
vanb
resist
marker
fungi
singl
assay
tissari
colleagu
evalu
clinic
perform
assay
use
patient
sampl
found
base
data
proveit
sepsi
show
sensit
specif
digit
pcr
dpcr
quantit
method
provid
sensit
reproduc
way
measur
amount
dna
rna
present
sampl
present
low
copi
number
similar
quantit
pcr
reagent
amplif
reaction
method
simpl
reproduc
need
quantit
standard
standard
curv
amplif
initi
sampl
mix
partit
multipl
individu
well
droplet
mani
end
contain
target
sequenc
amplif
number
posit
neg
reaction
determin
absolut
number
target
present
initi
reaction
mix
calcul
use
poisson
statist
dpcr
advantag
applic
requir
high
sensit
combin
accur
reproduc
enumer
small
number
target
method
obvious
use
quantif
viral
load
also
use
detect
rare
allel
determin
copi
number
variat
quantif
ng
librari
well
measur
gene
express
heterogen
multiplex
current
fdaapprov
commerci
avail
dpcr
system
unit
state
howev
sever
compani
raindrop
digit
pcr
system
raindanc
technolog
lexington
droplet
digit
pcr
system
biorad
hercul
ca
biomark
hd
system
qdpcr
ifc
fluidigm
corpor
south
san
francisco
ca
quantstudio
digit
pcr
system
life
technolog
carlsbad
ca
offer
dpcr
system
research
use
inform
dpcr
found
refer
diagnost
molecular
microbiolog
although
molecular
diagnost
gener
assum
impli
nucleic
acidbas
method
mass
spectroscopi
use
microbiolog
sinc
time
mass
spectroscopi
use
almost
exclus
identif
anaerob
analysi
volatil
volatil
shortchain
organ
acid
new
mass
spectroscopi
techniqu
provid
gener
tool
identif
microorgan
grow
coloni
cultur
plate
requir
minut
potenti
improv
significantli
turnaround
time
microbiolog
cultur
report
reduc
labor
cost
especi
coupl
laboratori
autom
becom
avail
upfront
cost
high
cost
per
test
low
rapid
result
low
cost
per
individu
result
impact
antibiot
usag
patient
outcom
shorten
hospit
stay
lower
total
cost
new
technolog
matrixassist
laser
desorptionion
time
flight
malditof
current
fdaapprov
malditof
instrument
avail
unit
state
rapid
identif
microorgan
one
develop
shimadzu
scientif
instrument
columbia
md
licens
biomerieux
durham
nc
second
manufactur
bruker
dalton
billerica
licens
siemen
healthcar
diagnost
tarrytown
ny
becton
dickinson
spark
md
great
benefit
quick
easi
accur
identif
microorgan
encourag
larger
laboratori
implement
system
routin
organ
identif
despit
initi
high
instrument
cost
microorgan
identif
malditof
base
observ
pathogen
organ
uniqu
protein
signatur
bacteri
cell
fix
matrix
irradi
laser
beam
releas
ioniz
protein
enter
vacuum
column
move
toward
detector
base
charg
mass
protein
signatur
check
match
larg
still
grow
databas
deriv
differ
genera
speci
microorgan
differ
instrument
differ
databas
govern
limit
laboratori
access
databas
contain
protein
signatur
potenti
agent
bioterror
although
endem
certain
area
unit
state
malditof
identifi
bacteria
aerob
anaerob
mycobacteria
fungi
analysi
organ
tougher
cell
wall
gramposit
bacteria
yeast
fungi
requir
slight
modif
procedur
hundr
abstract
articl
attest
abil
rapidli
accur
identifi
bacteria
fungi
genu
speci
level
malditof
identif
etiolog
agent
sepsi
gener
perform
pathogen
first
grown
blood
cultur
bottl
subcultur
onto
standard
solid
media
step
time
consum
lead
use
broadspectrum
empir
antibiot
increas
speed
identif
protocol
develop
use
malditof
directli
newli
posit
blood
cultur
bottl
although
use
sampl
contain
multipl
organ
data
also
accumul
illustr
abil
malditof
identifi
antibioticresist
organ
howev
work
need
area
malditof
could
becom
valid
altern
routin
antibiot
suscept
test
rapid
advanc
develop
laserinduc
breakdown
spectroscopi
lib
transform
element
analysi
techniqu
one
use
directli
identif
complex
materi
includ
clinic
microbiolog
specimen
grow
number
recent
articl
illustr
abil
lib
rapidli
detect
accur
identifi
variou
biolog
biomed
clinic
sampl
analys
sensit
specif
rapid
requir
sampl
prepar
lib
identifi
microorgan
base
determin
element
composit
lib
use
strong
laser
puls
atom
content
bacteri
cell
light
hightemperatur
spark
collect
analysi
peak
atom
emiss
spectrum
allow
identif
rel
quantif
atom
present
sampl
spectral
fingerprint
peak
ratio
compar
databas
lib
spectra
deriv
differ
genera
speci
microorgan
allow
identif
bacteri
genu
speci
yet
fdaclear
lib
system
rapid
identif
pathogen
microorgan
raman
spectroscopi
interest
also
recent
gener
possibl
use
raman
spectroscopi
rapid
identif
varieti
bacteria
raman
spectroscopi
use
interact
light
molecul
measur
function
group
vibrat
photon
incid
focus
laser
interact
molecul
caus
molecul
transit
excit
vibrat
state
accompani
correspond
energi
loss
photon
energi
loss
result
light
undergo
frequenc
shift
henc
chang
color
measur
spectrum
uniqu
bacteri
speci
check
databas
rapid
identif
pathogen
raman
spectroscopi
distinct
current
techniqu
eas
low
cost
high
speed
provid
inform
chemic
composit
structur
biomolecul
within
microorgan
thu
slight
chang
chemic
makeup
organ
determin
raman
spectroscopi
use
differenti
genera
speci
even
strain
studi
chouthai
colleagu
show
reliabl
rapid
accur
identif
candida
speci
use
raman
spectroscopi
detect
pathogen
possibl
complex
matric
soil
food
bodi
fluid
spectroscop
analysi
may
allow
determin
effect
antibiot
bacteria
multiplex
autom
digit
microscopi
time
laps
imag
acceler
pheno
system
autom
acceler
pheno
techniqu
axdx
acceler
diagnost
receiv
fda
approv
februari
perform
bacteri
identif
antibiot
suscept
test
directli
posit
blood
cultur
bottl
without
requir
isol
purifi
coloni
cut
almost
hour
time
identif
antibiot
suscept
test
techniqu
use
digit
microscopi
allow
identif
bacteri
pathogen
posit
blood
cultur
bottl
around
hour
antibiot
suscept
test
hour
later
succe
techniqu
fail
analyz
singl
cell
organ
identif
perform
use
multiplex
autom
digit
microscopi
fish
probe
describ
elsewher
articl
antibiot
suscept
test
perform
observ
growth
individu
live
immobil
bacteri
cell
presenc
antimicrobi
agent
phenotyp
antibiot
suscept
test
result
panel
standard
antibiot
requir
hour
blood
cultur
bottl
turn
posit
guid
appropri
antibiot
therapi
microscop
techniqu
reduc
mortal
morbid
axdx
identifi
perform
antibiot
suscept
test
gramposit
gramneg
bacteri
generaspeci
candida
speci
system
bacteri
cell
first
purifi
blood
cultur
growth
medium
gel
electrofiltr
follow
cell
immobil
via
electrokinet
concentr
fish
antibiot
suscept
test
laboratori
evalu
perform
accuraci
acceler
system
test
clinic
sampl
system
compar
result
standard
method
current
consist
combin
phenotyp
biochem
andor
malditof
techniqu
pathogen
identif
combin
antibiot
suscept
test
via
becton
dickinson
phenix
autom
microbiolog
system
data
reveal
high
sensit
specif
identif
pathogen
well
high
categor
essenti
agreement
antibiot
suscept
test
result
system
robust
averag
provid
identif
antibiot
suscept
test
result
hour
bottl
posit
marschal
colleagu
compar
perform
axdx
convent
culturebas
method
axdx
correctli
identifi
blood
stream
infect
bsi
episod
isol
cover
system
identif
panel
axdx
gener
antibiot
suscept
test
result
sampl
identifi
gramneg
pathogen
found
overal
categori
agreement
sensit
intermedi
resist
interpret
axdx
culturebas
antibiot
suscept
test
rate
minor
discrep
chang
sensit
resist
intermedi
major
discrep
major
discrep
lifescal
biosensor
rapid
antimicrobi
suscept
lifescal
affin
biosensor
santa
barbara
ca
use
reson
mass
measur
enumer
determin
mass
bacteria
expos
antibiot
allow
determin
antibiot
suscept
within
approxim
hour
beam
suspend
end
reson
specif
frequenc
mass
ad
beam
reson
frequenc
decreas
amount
relat
ad
mass
beam
suspend
vacuum
bacteria
growth
medium
pass
microchannel
beam
technolog
develop
life
scale
biosensor
make
determin
standard
plate
includ
minimum
inhibitori
concentr
plate
prepar
sensititr
thermoscientif
waltham
individu
bacteria
enumer
individu
mass
rapidli
determin
femtogram
g
determin
rapidli
pass
microchannel
beam
two
poster
present
asm
microb
demonstr
proof
concept
antibiot
suscept
determin
use
multipl
gramneg
organ
gener
use
clinic
laboratori
antibiot
suscept
test
control
organ
reson
mass
measur
standard
laboratori
antibiot
suscept
test
result
compar
twothird
antibiot
demonstr
essenti
agreement
standard
result
hour
less
wherea
standard
techniqu
requir
hour
two
antibiot
less
categor
agreement
requir
longer
incub
time
result
indic
rapid
antibiot
suscept
test
base
reson
mass
measur
produc
reliabl
antibiot
suscept
test
result
gramneg
strain
ongo
investig
plan
extend
result
gramposit
strain
valid
method
clinic
sampl
posit
blood
cultur
colorimetr
sensor
array
use
volatil
organ
compound
color
activ
indic
array
rapid
bacteri
identif
specid
specif
technolog
mt
lake
ca
blood
cultur
system
provid
organ
detect
identif
etiolog
agent
sepsi
grow
modifi
blood
cultur
bottl
rapidli
detect
alon
occur
similar
compar
blood
cultur
bottl
bacteria
grow
produc
characterist
volatil
organ
compound
voc
accumul
head
gass
cultur
medium
bottl
spectrum
voc
produc
characterist
given
genu
speci
bacteria
inexpens
dispos
array
substitut
top
bottl
built
proprietari
bottl
array
consist
chemic
indic
chang
color
differ
expos
voc
mixtur
allow
determin
voc
releas
first
instrument
use
techniqu
shown
amsterdam
european
societi
clinic
microbiolog
infecti
diseas
proofofprincipl
paper
lim
colleagu
demonstr
specid
fingerprint
detect
identif
voc
fingerprint
organ
pure
cultur
sensit
specif
respect
could
distinguish
strain
aureu
suggest
may
use
epidemiolog
purpos
well
furthermor
detect
rapid
organ
identif
array
detect
growth
almost
hour
faster
standard
system
whether
work
mix
infect
remain
determin
shrestha
colleagu
studi
abil
specid
array
identifi
panel
import
yeast
pathogen
bactalert
bottl
modifi
contain
array
compar
standard
bottl
inocul
ml
blood
either
unspik
spike
differ
quantiti
yeast
speci
bottl
contain
yeast
report
neg
yeast
posit
bottl
detect
correctli
regardless
wide
rang
inoculum
size
growth
colorimetr
sensor
array
detect
hour
faster
bactalert
system
mean
sensit
specieslevel
identif
colorimetr
sensor
array
time
growth
detect
increas
time
reach
almost
hour
growth
detect
cultureless
system
rapid
detect
identif
pathogen
directli
patient
specimen
magicplex
sepsi
realtim
test
seegen
magicplex
screen
pathogen
cover
sepsiscaus
pathogen
well
drug
resist
marker
methicillin
vancomycin
meca
vana
vanb
whole
blood
sampl
also
test
abl
identifi
pathogen
detect
previou
screen
step
addit
minut
gramposit
gramneg
fungi
antibiot
resist
gene
also
discrimin
magicplex
sepsi
test
requir
ml
patient
whole
blood
provid
test
result
within
hour
extract
microbi
dna
enrich
base
molzym
molysi
technolog
bremen
germani
enabl
dna
enrich
convent
technolog
autom
dna
isol
perform
seegen
seoul
korea
instrument
base
nordiag
arrow
technologysystem
pathogen
identifi
magicplex
sepsi
assay
streptococci
agalactia
pyogen
pneumonia
enterococci
e
faecali
e
gallinarum
e
faecium
staphylococci
epidermidi
haemolyticu
aureu
p
aeruginosa
acinetobact
baumannii
maltophilia
marcescen
b
fragili
typhi
klebsiella
pneumonia
k
oxytoca
p
mirabili
e
coli
e
cloaca
e
aerogen
c
albican
c
tropicali
c
parapsilosi
c
glabrata
c
krusei
fumigatu
magicplex
compat
rtcr
lifetim
technolog
hanoi
japan
realtim
pcr
biorad
smartcycl
ii
rtpcr
clinic
valid
magicplex
serra
colleagu
demonstr
detect
candida
dna
pediatr
patient
cultur
result
neg
howev
assay
also
falseneg
result
studi
least
ml
blood
sampl
inocul
versatrek
bottl
incub
c
hour
longer
dna
extract
carrara
colleagu
show
result
compar
studi
magicplex
standard
blood
cultur
patient
posit
result
posit
system
magicplex
blood
cultur
sensit
specif
respect
magicplex
sepsi
test
respect
blood
cultur
denina
colleagu
studi
pediatr
patient
found
magicplex
allow
increas
detect
septic
episod
howev
ziegler
cowork
found
test
detect
mani
organ
suspect
contamin
investig
increas
cutoff
valu
posit
conclud
magicplex
show
high
specif
chang
design
need
increas
pathogen
detect
viabil
clinic
laboratori
technic
improv
also
requir
autom
process
product
ivd
ce
mark
avail
unit
state
lightcycl
septifast
test
mgrade
septifast
roch
molecular
system
provid
rapid
identif
speci
level
common
etiolog
agent
bsi
bacteri
fungal
less
hour
directli
ml
whole
blood
without
prior
cultur
assay
target
multicopi
region
intern
transcrib
spacer
increas
sensit
detect
limit
approxim
colonyform
unit
cfu
ml
target
includ
gramneg
bacteria
relat
group
gram
posit
fungi
includ
aspergillu
fumigatu
test
design
run
instrument
manufactur
roch
combin
rapid
amplif
melt
point
analysi
rapid
result
relat
assay
also
detect
meca
gene
detect
aureu
subsequ
run
use
lightcycl
septifast
meca
test
mgrade
septifast
ce
mark
avail
unit
state
markota
colleagu
demonstr
sensit
specif
neg
predict
valu
comparison
standard
blood
cultur
suggest
system
use
supplement
standard
blood
cultur
sepsitestumd
sepsitestumd
molzym
use
ml
whole
blood
tissu
sampl
detect
bacteri
pathogen
yeast
sampl
prepar
dna
concentr
pcr
assay
amplifi
ribosom
sequenc
primer
sanger
sequenc
includ
assay
posit
detect
identifi
basic
local
align
search
tool
analysi
use
onlin
data
base
addit
kit
avail
fluid
swab
mani
research
use
colleagu
compar
sepsitest
blood
cultur
found
sensit
specif
neg
predict
valu
posit
predict
valu
system
fulli
autom
result
avail
quickli
test
approv
vitro
diagnost
europ
unit
state
biosystem
sepsi
solut
biosystem
recogn
us
market
fdaapprov
assay
diagnosi
candidemia
directli
blood
sampl
patient
hour
mri
small
instrument
use
pcr
follow
hybrid
probedecor
nanoparticl
microclust
hybrid
induc
chang
magnet
reson
signal
result
rapid
identif
candida
one
import
featur
techniqu
direct
use
blood
sampl
instrument
without
prior
process
step
also
benefit
high
sensit
enabl
system
detect
cfu
per
millilit
target
whole
blood
report
mylanaki
colleagu
c
kruseic
glabrata
lod
cfuml
c
tropicali
c
krusei
cfuml
c
albican
c
glabrata
cfuml
c
parapsilosi
neg
predict
valu
estim
rang
studi
popul
preval
candidemia
respect
bacteri
panel
anoth
assay
detect
bacteri
pathogen
directli
blood
patient
suspect
bacteremiasepsi
detect
escherichia
coli
k
pneumonia
pseudomona
aeruginosa
baumannii
aureu
enterococcu
faecium
expect
fda
clear
use
system
clinic
set
potenti
impact
patient
outcom
await
data
clinic
studi
qvella
fast
id
bsi
panel
qvella
blood
pathogen
detect
system
fast
id
bsi
panel
develop
identifi
bacteri
fungal
pathogen
directli
blood
sampl
less
hour
use
rrna
target
multiplex
pcr
bacteri
identif
system
benefit
also
tailor
electr
field
lysi
bacteri
cell
present
blood
sampl
follow
concentr
step
obtain
highli
concentr
purifi
bacteri
genom
materi
purifi
nucleic
acid
use
multiplex
real
time
revers
transcriptas
pcr
rapid
detect
identif
microorgan
directli
blood
fast
technolog
implement
fast
id
bsi
panel
integr
close
devic
design
fulli
autom
isol
concentr
lysi
well
amplif
detect
nucleic
acid
pathogen
whole
blood
sampl
perform
test
whole
blood
tube
insert
fast
id
bsi
panel
place
fast
analyz
follow
process
occur
automat
process
fast
id
bsi
panel
analyz
target
cell
isol
concentr
target
cell
electr
lysi
treatment
amplif
detect
bacteri
fungal
ribosom
target
spatial
multiplex
array
assay
detect
major
sepsiscaus
speci
system
shown
abl
identifi
polymicrobi
infect
spike
sampl
khine
colleagu
present
data
european
societi
clinic
microbiolog
infecti
diseas
regard
lower
lod
qvella
fast
system
lod
determin
approxim
cfuml
variou
cell
type
low
lod
consist
pathogen
concentr
typic
found
infect
whole
blood
sampl
dataset
detect
made
time
klebsiella
pneumonia
pseudomona
aeruginosa
e
faecium
c
albican
diagnost
molecular
microbiolog
c
glabrata
cfuml
aureu
detect
made
time
greater
cfuml
greater
time
cfuml
howev
less
detect
aureu
least
partli
attribut
inher
difficulti
accuraci
associ
spike
certain
gramposit
bacteria
low
concentr
qvella
blood
identif
system
design
detect
pathogen
isol
patient
sepsi
clinic
trial
system
expect
start
second
quarter
advanc
sequenc
technolog
known
ng
led
signific
advanc
basic
scienc
clinic
laboratori
medicin
includ
microbiolog
current
avail
ng
techniqu
base
use
clonal
amplicon
parallel
multistrand
sequenc
combin
highspe
highthroughput
data
analysi
made
ng
excel
tool
take
clinic
analysi
nucleic
acid
sequenc
new
level
ng
possibl
detect
quantifi
quasispeci
hiv
hcv
hepat
b
viru
circul
low
level
blood
infect
patient
learn
role
develop
resist
associ
treatment
failur
difficult
imposs
use
method
mention
previous
despit
increas
number
articl
applic
ng
system
found
way
routin
clinic
microbiolog
test
lack
fda
approv
high
cost
avail
altern
technolog
diagnost
microbiolog
viewpoint
ng
significantli
improv
abil
studi
makeup
entir
commun
microorgan
without
cultur
ng
provid
genet
sequenc
member
entir
microbi
commun
microbiom
determin
rel
frequenc
could
also
use
determin
gene
express
metabol
pathway
use
microbi
commun
although
current
beyond
scope
clinic
microbiolog
laboratori
mani
studi
human
microbiom
focus
relationship
microbi
commun
health
diseas
includ
exampl
effect
colon
microorgan
cardiovascular
diseas
ng
also
appli
rapid
investig
outbreak
hospit
set
discuss
herein
ngsbase
diagnost
microbiolog
system
current
fairli
advanc
develop
highlight
potenti
ng
improv
detect
identif
pathogen
clinic
laboratori
especi
involv
organ
may
difficult
imposs
identifi
situat
otherwis
technic
demand
system
base
nextgener
sequenc
identif
pathogen
clinic
specimen
kariu
digit
cultur
kariu
redwood
citi
ca
develop
ngsbase
test
detect
presenc
plasma
cellfre
dna
presum
deriv
infect
pathogen
amplif
human
dna
remov
proprietari
techniqu
ng
perform
total
nucleic
acid
enrich
microbi
sequenc
sequenc
align
pathogen
sequenc
bank
consist
publicli
avail
genet
inform
also
kariu
intern
data
thu
potenti
detect
thousand
infect
organ
system
uniqu
detect
sequenc
dna
virus
addit
bacteria
fungi
like
standard
organ
detect
assay
system
detect
bacteremia
fungemia
sever
studi
kariu
collabor
also
shown
system
abl
diagnos
infect
certain
highli
fastidi
organ
antibiot
render
infect
organ
nonviabl
system
could
also
detect
infect
organ
infect
outsid
bloodstream
organism
dna
releas
blood
includ
osteomyel
deep
infect
would
otherwis
requir
biopsi
patient
known
suspect
bacteremia
system
show
posit
agreement
neg
agreement
overal
agreement
standard
blood
cultur
comparison
clinic
diagnosi
system
show
posit
neg
agreement
respect
pathoquest
idtect
idtect
blood
pathoquest
pari
franc
also
combin
untarget
ng
sampl
prepar
process
genom
sequenc
databas
said
cover
clinic
relev
human
pathogen
first
cemark
octob
ngsbase
method
detect
bacteria
virus
patient
known
suspect
infect
directli
patient
blood
therebi
improv
pathogen
detect
biolog
sampl
pathoquest
technolog
combin
ng
platform
proprietari
sampl
prepar
process
proprietari
pathogen
genom
sequenc
databas
autom
analysi
softwar
cover
known
clinic
relev
human
pathogen
pariz
colleagu
use
prototyp
version
idtect
identifi
relev
pathogen
patient
difficulttodiagnos
popul
convent
test
applic
molecular
test
disciplin
infecti
diseas
diagnosi
prognosi
manag
matur
exponenti
last
year
futur
improv
doubt
avail
addit
mileston
sensit
specif
cost
reduct
turnaround
time
specimen
procur
result
effect
expediti
patient
manag
